Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

gpASIT+TM

Phase 1Biologic

BBioTech Tools S.A.

gpASIT+TM is one of 55 biologic programs targeting Conjunctivitis. It is currently in Phase 1.

2

Indications

8

Total Trials

0

Active Trials

54

Competitors

Pipeline

Status by Indication[3][1]

Indication

ConjunctivitisActive, not recruiting

Allergic RhinitisActive, not recruiting

ConjunctivitisPhase 1

Active, not recruiting

Allergic RhinitisPhase 1

Active, not recruiting

Competition

Competitive Landscape

271 competitors in Allergic Rhinitis

#DrugCompanyPhaseTrials

Kenalog

BBassett Healthcare

Comparator: Statins

Standard Adjuvant ET

Flonase

Asmanex

Product CM9241GRU

AAche Laboratorios Farmaceuticos S.A.

HL151

HHanlim Pharm. Co., Ltd.

Veramyst

Singulair

Xolair

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Conjunctivitis5 trials

Clinical Efficacy and Safety of a Subcutaneous Immunotherapy With gpASIT+™ in Patients With Grass Pollen-induced Allergic Rhinoconjunctivitis

Completed·BBioTech Tools S.A.·Phase 3·NCT02560948·554 enrolled

Clinical Efficacy and Safety of Subcutaneous Immunotherapy With gpASIT+™ in Patients With Grass Pollen-induced Allergic Rhinoconjunctivitis

Unknown status·AASIT Biotech S.A.·Phase 3·NCT03724240·624 enrolled

Clinical Safety and Tolerability Study of gpASIT+TM and gpASIT+TM/Immunoregulating Adjuvant to Treat Seasonal Grass Pollen Rhinoconjunctivitis

Completed·BBioTech Tools S.A.·Phase 1·NCT01111279·27 enrolled

Show 2 more trials

Clinical Efficacy and Safety of gpASIT+TM to Treat Seasonal Allergic Rhinoconjunctivitis

Completed·BBioTech Tools S.A.·Phase 2·NCT01308021·202 enrolled

Safety Study of Grass Pollen-derived Peptides to Treat Seasonal Allergic Rhinoconjunctivitis

Completed·BBioTech Tools S.A.·Phase 1/2·NCT00833066·54 enrolled

Allergic Rhinitis1 trial

Safety and Tolerance Study of Grass Pollen-derived Peptides to Treat Allergic Rhinitis

Completed·BBioTech Tools S.A.·Phase 1·NCT00813046·8 enrolled

Hay Fever1 trial

Safety of gpASIT+TM Subcutaneously Administered to Hay Fever Patients With or Without Immunoregulating Adjuvant

Completed·BBioTech Tools S.A.·Phase 2·NCT01506375·24 enrolled

Immunogenicity1 trial

Safety, Clinical Tolerability and Immunogenicity of Increasing Doses of gpASIT+TM

Completed·BBioTech Tools S.A.·Phase 2·NCT02156791·61 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for gpASIT+TM. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — gpASIT+TM compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for gpASIT+TM. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — BioTech Tools S.A. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: BBioTech Tools S.A.

Related News